Chronic pelvic and genital pain in transgender care remains undermapped
Chronic pelvic pain and related genital pain in transgender and gender-diverse people has moved into sharper clinical view through a scoping review in The Lancet. The topic sits at the intersection of pain medicine, sexual health, urology, gynecology, and gender-affirming care, yet it has often been treated as a peripheral complaint rather than a core quality-of-life issue. In practice, persistent pelvic or genital pain can affect voiding, sexual function, mobility, sleep, mental health, and willingness to seek medical care at all.
A scoping review is the right tool for a question like this because the literature is often fragmented before it is mature. It can identify where evidence exists, where terminology varies, and where the field has left important questions unanswered. For transgender and gender-diverse patients, that matters because pain is frequently filtered through a clinical system that was built around cisgender assumptions about anatomy, reproductive history, and gendered symptom patterns. When those assumptions go unchallenged, pain can be mislabeled, underinvestigated, or attributed too quickly to anxiety, hormone therapy, surgical history, or dysphoria alone.
Why this pain syndrome is clinically difficult to ignore
Persistent pelvic pain is rarely a single-diagnosis problem. In transgender and gender-diverse patients, the differential can span musculoskeletal strain, pelvic floor dysfunction, neuropathic pain, postsurgical scar-related pain, hormonal effects on mucosa and tissue sensitivity, bladder pain syndromes, bowel-related disorders, and irritation or injury related to sexual activity or gender-affirming devices. Genital pain may also emerge in the setting of tissue changes after endocrine treatment or surgery, but the biological pathway is not always simple or linear.
Pain in this setting can become self-reinforcing. Anticipatory guarding, pelvic floor hypertonicity, and avoidance of exams or intimacy can intensify symptoms over time, while distress related to misgendering or prior negative encounters can make assessment harder. In a patient who has already had to explain their body repeatedly, even a technically competent evaluation can fail if it does not begin with careful anatomy-based questioning and a nonjudgmental frame.
One missed conversation can shape years of symptoms.
What a scoping review can clarify for frontline clinicians
The value of a scoping review lies in its ability to map the structure of the evidence rather than force a narrow conclusion. For a topic as underdeveloped as chronic pelvic and genital pain in transgender and gender-diverse people, that usually means asking what kinds of studies have been done, what patient groups were included, how pain was defined, and whether outcomes were measured in a way that matters to patients. It can also reveal whether the literature separates transgender men, transgender women, and nonbinary people, or whether different experiences have been collapsed into a single category that obscures important clinical differences.
That kind of mapping has direct bedside consequences. If the literature relies on small observational series, case reports, or extrapolation from cisgender populations, then clinicians have to be especially cautious about assuming that standard pathways will work the same way here. Hormonal status, surgical anatomy, use of dilators or prostheses, menstrual suppression, urinary symptoms, trauma history, and sexual practices can all shape the pain phenotype. A generic chronic pain template is not enough.
The review also likely serves a second purpose: it exposes how little standardized terminology exists. In pelvic pain research, the words used to describe a symptom often determine who gets counted. If studies use inconsistent labels such as genital discomfort, dyspareunia, vulvar pain, perineal pain, or pelvic floor pain without precise anatomical and temporal definition, meaningful synthesis becomes difficult. For transgender and gender-diverse care, that problem is amplified because anatomy, identity, and treatment history do not always line up in conventional ways.
Anatomy, hormones, and surgery cannot be treated as interchangeable explanations
Clinicians often face pressure to reduce pelvic pain in transgender patients to one dominant cause, especially if the patient is receiving gender-affirming hormones or has undergone surgery. That shortcut is clinically unsafe. Hormonal therapy may influence tissue characteristics, lubrication, and mucosal integrity, while surgery can alter nerve pathways, scar architecture, and pelvic floor mechanics. Yet none of those factors excludes other causes of pain, including inflammatory, urologic, gastrointestinal, or neuropathic disease.
The same caution applies in the opposite direction. Not every pelvic symptom should be assumed to reflect a gynecologic disorder simply because the patient has retained reproductive organs. A careful history needs to account for the body as it exists now, not the body presumed by the chart. For many patients, the first therapeutic intervention is not a procedure or prescription but a careful, affirming diagnostic approach that does not force them to choose between identity and symptom relief.
Pain medicine is moving toward more individualized phenotyping, and this population needs that shift urgently. The likely clinical message from a scoping review in this area is not that one treatment will solve the problem, but that the field has not yet built the evidence base needed to recommend with confidence which evaluation pathways or interventions best fit which patients.
Care gaps are part of the disease burden
When evidence is sparse, access barriers become part of the illness itself. Patients with chronic pelvic or genital pain may encounter clinicians who are unsure how to examine them, reluctant to ask anatomy-specific questions, or unfamiliar with gender-affirming terminology. Others may avoid care because prior encounters were invasive, invalidating, or physically painful. Over time, that can delay diagnosis of treatable disorders and leave patients managing symptoms alone.
The review’s existence signals a larger clinical need: structured research that measures pain in ways that are relevant to transgender and gender-diverse people, and care pathways that are safe enough for patients to use. That means more than acknowledging the problem in principle. It requires validated symptom measures, careful phenotyping, and treatment studies that do not assume a cisgender baseline as the only reference point.
A meaningful next step will be determining whether future studies can separate the biological drivers of pain from the social and structural harms that intensify it. For now, the core message is straightforward. Chronic pelvic and genital pain in transgender and gender-diverse people is common enough, complex enough, and consequential enough that it should no longer sit at the margins of clinical research.